← All trials
NCT01642212
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2012
- Primary completion
- Oct 1, 2014
- Completion date
- Oct 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 93
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ShireLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- Rhode Island HospitalOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- University of ArizonaOverall official - principal investigator
- Children's Center for Digestive HealthOverall official - principal investigator
- Options Health Research, LLCOverall official - principal investigator
- University of California, IrvineOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- University of ColoradoOverall official - principal investigator
- Ohio State UniversityOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- University of IowaOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of UtahOverall official - principal investigator
- University of California, San DiegoOverall official - principal investigator
- Tufts UniversityOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Virginia Polytechnic Institute and State UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.